2025.05. 19 本文字数：2606，阅读时长大约5分钟 作者 | 第一财经 曹璐 今年以来，历经四年连跌的医药板块似乎迎来一波曙光，不少医药主题基金净值回暖明显。Wind数 据显示，截至5月16日，超八成医药相关主题基金上涨，11只产品涨幅超30%，其中长城医药产业精 选A以42.48%的年内回报领跑，这类产品的业绩首尾差距已经超过53个百分点。 业 绩 分 化 背 后 ， 港 股 创 新 药 的 强 势 表 现 尤 为 瞩 目 ， 相 关 指 数 （ 港 股 通 创 新 药 指 数 ） 年 内 上 涨 28.37%，重仓与否也成为医药主题产品的业绩"胜负手"。那么，港股创新药为何会有如此亮眼的表 现，这是否意味着医药赛道已经重新崛起？ "创新药是大类科技资产里基本面相对扎实的品种，预计今年其股价走势有望比过去几年更加顺 畅。"长城基金基金经理梁福睿对第一财经表示，创新药这波强势行情的底层逻辑在于，科技资产牛 的背景下，创新药产业的逻辑在不断强化。 交银医疗健康基金经理徐嘉辰则认为，创新药年初以来的行情不是偶然，也不完全是科技创新风格的 外溢，而是中国创新企业的国际竞争力明显提升，伴随的是整个中国创新 ...

Group 1: Financial Performance and Growth - In 2024, the company achieved over 1 billion RMB in sales for 10 products, with the core product, Yunnan Baiyao aerosol, generating over 2.1 billion RMB, a year-on-year increase of over 26% [2][3] - Other traditional Chinese medicine products also saw significant growth, with Pudilan anti-inflammatory tablets reaching nearly 200 million RMB, a year-on-year increase of over 22% [2][3] - The company aims to optimize its product system and provide comprehensive operational plans to achieve strategic growth in major disease treatment areas [3][4] Group 2: Strategic Development and Market Positioning - The company has established four strategic positions across its business segments: Traditional Chinese Medicine Resources, Pharmaceutical, Health, and Pharmaceutical Commerce [3][4] - It plans to enhance its product matrix in the pharmaceutical industry and strengthen its channel capabilities in hospitals [3][4] - The company is focused on international business growth, leveraging its geographical advantages and policies to expand overseas market sales [8][11] Group 3: Digital Transformation and AI Integration - The company is implementing a digital development plan (2022-2026) that integrates AI technology across all industry chain segments to drive transformation and innovation [5][6] - It has developed a digital ecosystem for traditional Chinese medicine, enhancing efficiency in product development and supply chain management [5][6] Group 4: Product Development and Market Expansion - The company is focusing on major health issues related to aging and has launched several key products targeting these markets [7][8] - It is actively developing innovative drugs and has received clinical trial approvals for new products, including a diagnostic nuclear medicine project [10][11] Group 5: Brand Management and Investor Relations - The company is working to reshape its brand perception beyond just toothpaste, emphasizing its heritage in traditional Chinese medicine and expanding its product offerings [12][13] - In 2024, the total cash dividend amounted to 4.279 billion RMB, accounting for 90.09% of the net profit attributable to shareholders [14]

文 | 一点财经，作者 | 赵同，编辑 | 邹珺 王小川，这位头顶"天才少年"光环的清华学霸、搜狗输入法创始人、中国互联网初代技术偶像，正迎来 人生中最难啃的硬骨头。 他在2023年创立的百川智能，被称为"大模型六小虎"之一。今年4月，王小川在全员信中罕见地反思过 去两年工作的不足，过去两年百川智能战线过长，接下来将收缩战线、押注医疗AI。 无疑，王小川在AI领域打了一场败仗。这场战略收缩，被外界解读为"断臂求生"——曾经对标Open AI 的野心，终究败下阵来，医疗成为王小川搭上AI这趟列车的最后一块跳板。 但更深层的危机还没有停止。 缺少B端业务的输血，王小川押注极度烧钱的AI医疗会面临更大风险。更为紧迫的是，王小川认为组织 是AI创业中最重要的因素，然而2024年下半年以来，百川智能有多位核心高管相继离职，整个组织也 在变得臃肿，团队的目标变得摇摆。 天才CEO，为何管不住人呢？ 王小川的大撤退 王小川曾给资本市场画过一张"AI大饼"：底层模型对标OpenAI，C端产品要做中国的ChatGPT，B端横 扫金融、教育、法律等领域，医疗领域还要造出"AI医生"。 这时候的百川智能确实风光——左手握着通用大模 ...

Core Viewpoint - The company reported a decline in revenue and net profit for Q1 2025, primarily due to stricter control over drug usage in medical institutions and the impact of centralized procurement policies [1][2]. Group 1: Financial Performance - In Q1 2025, the company achieved revenue of 5.317 billion yuan, a year-on-year decrease of 7.93% [1]. - The net profit attributable to shareholders was 277 million yuan, down 7.66% year-on-year [1]. - The decline in performance was attributed to reduced drug usage by core clients in medical institutions and the impact of centralized procurement [1][2]. Group 2: Future Growth Points - The company plans to continue its strategy of collaboration across drug and medical device sectors, focusing on high-quality products and innovative projects [2]. - Emphasis will be placed on developing prescription external projects and integrating new technologies like AI to enhance retail business transformation [2]. - The company aims to strengthen its industrial segment by expanding its market presence outside the province and improving R&D capabilities [2]. Group 3: AI and Technology Integration - The "AI + Medical" service plan aims to create a comprehensive AI service system for both hospital and retail environments, enhancing supply chain efficiency and patient care [2]. - The AI assistant "A Gui Pharmacist" will provide health management services, including medication tracking and patient education [2]. Group 4: Industry Outlook - The pharmaceutical industry is expected to continue expanding due to an aging population and improvements in the healthcare system [2]. - The industry is undergoing a transformation characterized by stronger compliance, digitalization, and value-based competition [2]. Group 5: Risk Management and Financial Strategy - The company is focusing on high-quality sales and risk prevention, including measures to improve cash flow and reduce reliance on guarantees [3]. - Strategies include categorizing clients based on creditworthiness and payment capabilities to enhance sales and collection efficiency [3]. Group 6: Shareholder Engagement - The company plans to implement the profit distribution plan for 2024 within two months after approval at the shareholders' meeting [3].

Group 1 - The Hong Kong stock market opened lower on May 19, with the Hang Seng Index down 0.73% and the Hang Seng Tech Index down 1.58% [1] - The Hong Kong Innovative Drug ETF (159567) rose by 0.58% with a turnover rate of 8.02% and a trading volume exceeding 1.15 billion yuan, indicating active trading [1] - The innovative drug ETF closely tracks the Hong Kong Stock Connect Innovative Drug Index, reflecting the performance characteristics of biotech companies listed in Hong Kong [1] Group 2 - The pharmaceutical sector has shown a strong rebound this year, with several pharmaceutical funds reporting net value increases exceeding 30% [1] - Institutions are focusing on investment opportunities in AI healthcare, brain-computer interfaces, and innovative drugs following a period of deep adjustment in the pharmaceutical sector [1] - Guojin Securities emphasizes that innovative drugs and certain semi-innovative drugs remain key investment areas, with upcoming policy changes and data releases expected to catalyze stock price movements [1] Group 3 - Guoxin Securities highlights the rapid growth phase of the innovative drug sector, driven by commercialization and external licensing, which is accelerating revenue growth and profitability [2] - The traditional Chinese medicine sector faces short-term pressure but retains long-term branding and innovation potential [2] - The medical device sector is under short-term pressure due to slow policy implementation and inventory issues, but there are expectations for recovery driven by improved bidding processes [2]

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical industry [4] Core Views - The pharmaceutical index increased by 1.27% from May 12 to May 16, outperforming the CSI 300 index by 0.16% [5] - The report emphasizes the importance of innovation, international expansion, and the aging population as key growth drivers for the industry [38] - Long-term growth potential is highlighted for companies like Changchun High-tech, which has a strong sales capability and a developing innovative pipeline [5][9] Summary by Sections 1. Growth Hormones and Innovative Drug Pipeline - Changchun High-tech's stock price has experienced various phases since 2018, influenced by industry dynamics and pricing pressures from local procurement [9] - The company has maintained revenue above 10 billion CNY despite challenges, with a significant increase in R&D investment since 2020, totaling 8.5 billion CNY from 2020 to 2024 [12][13] - The innovative pipeline includes drugs for various conditions, with significant progress in clinical trials for products like Fuxin Qibai monoclonal antibody [18][24] 2. Industry Perspective - The pharmaceutical sector has shown resilience with a year-to-date increase of 2.48%, and a notable number of stocks have performed well [38] - The report identifies several key factors for future growth, including the maturation of domestic innovation, improved international competitiveness, and the increasing demand driven by an aging population [55] - The report suggests a focus on innovative pharmaceuticals, medical devices, and high-barrier industries as potential investment opportunities [5][6]

Group 1 - The pharmaceutical sector has experienced a nearly five-year correction since a strong rally from 2019 to 2020, but investment is gradually warming up this year driven by innovative drug concepts [1] - Wan Minyuan, a fund manager with a medical background, believes that the most difficult times for the pharmaceutical industry may have passed, with a relatively optimistic outlook on the sector's performance [1][4] - The investment strategy of Wan Minyuan emphasizes safety and a contrarian approach, focusing on buying when the market is less interested and selling when it is more enthusiastic [2][3] Group 2 - Wan Minyuan's investment philosophy is rooted in maintaining a high win rate by ensuring correct decisions outweigh incorrect ones, which is crucial for sustainable and predictable returns [2][3] - The pharmaceutical sector is expected to see improvements in 2025 due to the gradual resolution of multiple factors that have constrained its performance, including favorable policy changes [4][5] - Key drivers for long-term growth in the pharmaceutical industry remain unchanged, such as population aging, changes in disease patterns, and the supply of innovative technologies [5] Group 3 - Wan Minyuan focuses on companies with stable operations and emphasizes the importance of prudent financial management, avoiding overly aggressive accounting practices [3][5] - The investment strategy includes a long holding period for core positions, with a disciplined approach to selling based on specific criteria such as valuation bubbles and significant deviations from expected company performance [5][6] - Wan Minyuan identifies three main investment opportunities in the pharmaceutical sector: innovative drugs and medical devices, recovery in pharmaceutical consumption, and low price-to-book ratio assets [6][7] Group 4 - The interest in innovative drugs is growing, with an increase in upfront payments for licensing deals, although A-share market valuations for innovative drugs are currently high [7] - Wan Minyuan is also expanding investment horizons beyond the pharmaceutical sector, looking at domestic demand and technology sectors, particularly in undervalued assets in the Hong Kong market [7]

Group 1 - The establishment of the "Binhai Artificial Intelligence Medical Device Innovation Industry Alliance" aims to integrate innovative resources and promote deep integration of AI and medical device industries, creating a collaborative and open innovation ecosystem [1] - The "Binhai G3LAB High-end Medical Device Innovation Platform" has been launched to gather policy, capital, and industry chain resources, focusing on three cutting-edge areas: structural heart disease, neurointervention, and endoscopic treatment [1] - Experts highlight that AI medical device products are in the early stages of development, with a need for improved R&D innovation and regulatory capabilities, addressing challenges across the industry chain is a common challenge faced by the industry [1] Group 2 - The R&D cycle for high-end medical devices typically lasts 5-8 years, and the platform's support will alleviate financial pressures and regulatory challenges for innovative companies, particularly in the "AI + medical" integration technology [2] - The future development of AI medical devices requires collaboration among industry, academia, research, and medical sectors to integrate clinical needs with engineering innovation, establishing compliant and efficient data platforms to accelerate technology transfer and application [2] - AI is reshaping the paradigm of device R&D, enhancing innovation and redefining products, with companies leveraging AI to mine data, identify technological gaps, and develop innovative solutions that improve diagnostic accuracy [2] Group 3 - AI's application in cardiovascular diagnosis and treatment has gained attention, with significant advancements in recent years due to progress in data, algorithms, and computing power [3] - The focus of AI applications has primarily been on cardiovascular imaging and single-modal imaging research, while multi-modal imaging and generative AI represent the forefront of cardiovascular imaging research [3]

Core Insights - OpenAI has launched HealthBench, an open-source benchmark for evaluating the performance and safety of large language models in the healthcare sector, which has sparked widespread discussion in the industry [1][3] - The benchmark was developed with the participation of 262 practicing doctors from 60 countries and integrates 5,000 real medical dialogue data, utilizing 48,562 unique scoring criteria created by doctors for meaningful open assessments [1][3] - The introduction of HealthBench is expected to enhance the scientific and comprehensive evaluation of AI medical models, accelerating the application of AI technology in healthcare and providing new development opportunities for related companies [1][3] Group 1: HealthBench Overview - HealthBench consists of 7 themes and 5 evaluation dimensions, focusing on areas such as emergency referrals and professional communication, with dimensions including accuracy and contextual understanding [3][4] - OpenAI has also introduced two special versions of HealthBench: HealthBench Consensus, which includes 34 critical evaluation dimensions verified by doctors, and HealthBench Hard, which presents more challenging assessment scenarios [4] - The credibility of HealthBench has been supported by a meta-evaluation comparing model scores with human doctor scores, showing high consistency in 6 out of 7 evaluation areas [4] Group 2: Trends in AI Healthcare Applications - The AI healthcare market is projected to grow at an annual rate of 43% from 2024 to 2032, potentially reaching a market size of $491 billion [6] - AI is expected to enhance healthcare accessibility and efficiency, addressing issues like personnel shortages in hospitals and improving diagnostic accuracy [6] - The evolution of AI in healthcare has transitioned from rule-driven to data-driven approaches, now entering a multi-modal integration phase, allowing for better understanding and modeling of diverse medical data [6][7] Group 3: Future Directions in AI Models - The focus of competition among large models has shifted from merely increasing parameter size to optimizing model efficiency and performance under limited computational resources [7] - Key trends in AI applications within the pharmaceutical industry include the emergence of models as products, local and edge deployment, and rapid expansion of AI applications in research and development [7][8] - The pharmaceutical industry is expected to see a rise in specialized models tailored for specific scenarios, enhancing the adaptability and effectiveness of AI solutions [7][8]

Core Insights - The establishment of the world's first hospital operated entirely by 42 artificial intelligence doctors marks a significant advancement in AI-driven healthcare in China [1][2] - This AI hospital integrates cutting-edge technology across 21 medical departments, showcasing China's commitment to leveraging AI in medical care [1] - The AI doctors utilize large language models to autonomously communicate and manage a complete patient care process, from pre-hospital procedures to follow-up [1] Summary by Sections - **AI Hospital Operations** - The AI hospital processed over 10,000 virtual patients within a few days, demonstrating its efficiency compared to human doctors who would typically take about two years to handle the same volume [1] - The AI system continuously learns from vast medical literature to optimize its diagnostic and treatment skills [1] - **Impact on Healthcare** - This innovation is expected to reduce the workload of human doctors, decrease diagnostic errors, and improve treatment consistency [1] - The development emphasizes the importance of adhering to national medical regulations while exploring effective collaboration between AI and human medical staff [2] - **Future of AI in Medicine** - The AI hospital's success provides a forward-looking perspective on how AI can enhance patient experience and build trust in medical applications [2] - The milestone event highlights the rapid growth of AI as a key component of medical infrastructure in China, addressing modern medical challenges through a complementary approach with human intelligence [2]